bluuebunny/crossref_metadata_2025_split huggingface dataset:
Diagnostic utility of magnetic resonance imaging in autoimmune encephalitis: prognostic implications
Authors: Narayanan Nambiar Poornima , Manisha KY , Nandana Jayakumari , Menon Ramshekhar N , Vinayagamani S , Thomas Bejoy , Radhakrishnan Ashalatha 
Published: January 2025

Background The role of imaging in autoimmune encephalitis (AIE) remains unclear, and there are limited data on the utility of magnetic resonance imaging (MRI) to diagnose, treat, or prognosticate AIE. Purpose To evaluate whether MRI is a diagnostic and prognostic marker for AIE and assess its efficacy in distinguishing between various AIE subtypes. Material and Methods We analyzed data from 96 AIE patients from our prospective autoimmune registry. MRI sequences examined were FLAIR, diffusion, SWI, T2WI, ASL, and contrast enhancement. Short-term outcomes were measured using the Modified Rankin Scale (mRS) at discharge; long-term outcomes were assessed with the Functional Independence Measure (FIM) at 6 months. Results MRI confirmed AIE in cases of new-onset seizures (82.1%, P < 0.001) and dementia (100%, P = 0.02). Antibody-negative AIE exhibited significant multifocal FLAIR abnormalities compared to antibody-positive cases ( P = 0.002). LGI1 and CASPR2 encephalitis frequently involved the mesial temporal region ( P = 0.004), while ASL revealed hyperperfusion of the contralateral basal ganglia in faciobrachial dystonic seizures ( P = 0.016). GAD65 encephalitis predominantly affected the cerebellum ( P = 0.002), and NMDA encephalitis showed contrast enhancement in five cases ( P = 0.045). MRI was not useful for predicting short-term outcomes but was associated with long-term outcomes; specifically, a normal MRI was linked to a better long-term outcome in 47.8% of patients ( P = 0.035), and resolution of abnormalities correlated with a favorable FIM score (>54) in 76.7% ( P = 0.016). Conclusion MRI is valuable for early detection of seizures or dementia as initial manifestations of AIE and for differentiating AIE subtypes. Follow-up MRI is significant in predicting long-term outcomes.
Evidence-based Interventions for Youth With Concurrent Mental Health and Substance Use Disorders: A Scoping Review: Interventions fondées sur des données probantes pour les jeunes atteints de troubles concomitants de santé mentale et liés à l’usage de substances psychoactives : une étude de la portée
Authors: Marshall Tyler , Reeson Matthew , Loverock Alexandra , Lewis Ariana E. , King Ian , Ilyas Raffay , Dixon Celine Caruso , Viste Dylan , Azer Brandon , Chow Ethan , Safi Fahad , Kennedy Megan , Abba-Aji Adam , Greenshaw Andrew J. 
Published: January 2025

Background Mental health and substance use disorders typically onset during youth and commonly co-occur. Integrated treatment of two or more co-existing mental health and substance use disorders (i.e., concurrent disorders) is increasingly prevalent in real-world clinical settings. However, the depth of the evidence base on best practices remains unclear. Objectives This scoping review aimed to identify, map and summarize peer-reviewed studies of interventions for concurrent disorders in youth. Methods Six electronic health databases were systematically searched, in addition to a hand search of the reference lists of relevant systematic reviews. Only peer-reviewed studies of interventions treating concurrent disorders (i.e., simultaneous treatment of two or more disorders) in youth (10–29 years old) were eligible. Two independent reviewers conducted screening and data extraction. Results were charted according to studies employing pharmacological and non-pharmacological interventions. Results Thirty peer-reviewed studies were included, 19 (63.3%) were randomized controlled trials (RCTs). Most studies enrolled participants with an unspecified substance use disorder (n=17, 56.7%), while alcohol use was the primary substance use disorder in seven (23.3%) studies, followed by cannabis use disorder in six (20.0%) studies. Mood disorders (e.g., depression, dysthymia) were the most common concurrent mental health disorders comprising 15 (50%) studies, followed by nine (30.0%) studies of behavioural disorders (e.g., ADHD) and five (16.7%) studies of unspecified psychiatric disorders. Eighteen (60.0%) studies (n=1,699 participants) investigated the effectiveness of various non-pharmacological interventions, while 12 (40.0%) studies examined pharmacotherapies (n=765 participants). Conclusion Although several RCTs were identified, substantial clinical and methodological heterogeneity was evident among the studies (e.g., patients with multiple disorders, and multi-faceted interventions). Smaller systematic reviews focused on specific interventions (e.g., behavioural therapies) and concurrent disorders (e.g., depression and substance use) may be warranted. Due to considerable heterogeneity, more RCTs are needed before conducting larger systematic reviews or meta-analyses.
Analysis of real-world safety, tolerability, and cost efficiency of Sub-Cutaneous administration of Daratumumab in Manitoba
Authors: Quinlan Kaitlin , Geirnaert Marc , Kotb Rami , Dao Vi , Minuk Leonard , Kasian Jayne , Rimmer Emily 
Published: January 2025

Introduction Daratumumab is an anti-CD38 monoclonal antibody used in the treatment of myeloma and other related disorders. To mitigate the risk of infusion related reactions with IV Daratumumab the product monograph suggested a slow administration schedule that extends over several hours. 1 This leads to a significant burden for the outpatients’ treatment administration units and indirect costs to the patients such as time toxicity. Time toxicity is the time spent coordinating care and making frequent visits for follow-up and treatment. 2 In 2020 the COLUMBA trial 3 demonstrated that subcutaneous Daratumumab has a similar efficacy and safety profile as intravenous Daratumumab with considerably less side effects. 1 This retrospective study aims to document our local real-world experience with subcutaneous Daratumumab, with special emphasis on reducing time toxicity. Methods Patients with a plasma cell disorder over the age of 18 who had received at least one dose of subcutaneous Daratumumab between March 2022 and March 2023 were included. Data for this retrospective study was collected from Aria, which included: baseline patient demographics (gender, age); prior exposures to intravenous Daratumumab; and, whether a reaction to either intravenous or subcutaneous Daratumumab occurred. Descriptive statistics were used to summarize the data. Results A total of 197 patients were included in the analysis. There were no recorded reactions to subcutaneous Daratumumab. Conclusions The results of our study were used to eliminate our facility's 3-h post-injection observation period. In the future we plan to publish another study on the cost efficiency of subcutaneous Daratumumab.
Signalment, clinicopathological findings, management practices and comorbidities in cats with diabetes mellitus in Germany: cross-sectional study of 144 cases
Authors: Guse Bente , Langenstein Judith , Bauer Natali , Hazuchova Katarina 
Published: January 2025

Objectives The aim of this study was to describe signalment, clinicopathological findings, management practices and the occurrence of comorbidities in feline diabetes mellitus (DM) in Germany. Methods This was a cross-sectional study using questionnaires and laboratory submissions to a commercial laboratory, Antech Lab Germany, between May 2021 and July 2022. Inclusion criteria were diagnosis of DM by the attending veterinarian and submission of a completed questionnaire besides blood samples. Laboratory testing included haematology, serum biochemistry, concentration of total thyroxine (TT4), insulin-like growth factor 1 (IGF-1), cobalamin (COB), fructosamine, b-hydroxybutyrate and DGGR (1,2- O-dilauryl- rac-glycero-3-glutaric acid-[6′-methylresorufin] ester) lipase activity. Data are presented as the median (range) and analysed by non-parametric tests. P <0.05 was considered statistically significant. Results The median (range) age of the 144 diabetic cats at diagnosis was 11 years (0.9–18.7), 66.4% were male, 84.6% were domestic shorthair, 50.4% were currently overweight and 61.5% were previously overweight (body condition score >5/9). Most cats were treated with insulin (84%), most commonly protamine zinc insulin (57.5%). Blood glucose curves or continuous glucose monitoring alone or in combination with other methods were performed to adjust insulin therapy in 70.6% of cats. Based on questionnaires, 78.6% were poorly controlled and 21.4% were well controlled. Increased TT4 occurred in 3/139 and hyperthyroidism was known in 5/139 cats (frequency of known/suspected hyperthyroidism: 5.8% [n = 8/139]); 17.5% (n = 17/97) had increased IGF-1 (IGF-1 >746 ng/ml, cut-off for hypersomatotropism with the chemiluminescence assay used in this study); 24.5% (n = 34/139) had COB <295.2 pmol/l and 54.2% (n = 78/144) had increased DGGR. Cats with IGF-1 >746 ng/ml were receiving a higher insulin dose than cats with IGF-1 ≤746 ng/ml (median 1.63 vs 0.86 U/kg/day, P = 0.018). Conclusion and relevance Increased DGGR and increased IGF-1 indicating hypersomatotropism are common in diabetic cats and should be tested for. Almost one-quarter of diabetic cats might require COB supplementation.
Dose Escalation of Adalimumab in Patients with Hidradenitis Suppurativa: A Retrospective Case Series
Authors: Caudrelier Nicolas , Veillette Hélène 
Published: January 2025

Background: Adalimumab is a central treatment for moderate-to-severe hidradenitis suppurativa (HS). However, half of patients treated with adalimumab for HS do not achieve a clinically significant response. Data on non-immunological factors correlating clinical response and adalimumab blood concentration are scarce. Objectives: To determine whether increasing adalimumab dose to 80 mg weekly can improve the clinical outcome of patients unresponsive to adalimumab 40 mg weekly. To identify parameters influencing disease activity and those modifying serum adalimumab concentration. Methods: This is a retrospective case series from a tertiary dermatology clinic, comprising 40 patients with moderate-to-severe HS with suboptimal response to the FDA-approved dose of adalimumab. All patients had a measurement of blood adalimumab concentration. Depending on their dosage, some patients had their adalimumab dose increased to 80 mg weekly while others stayed at 40 mg dose weekly. Chi-squared and ANOVA tests were used for data analysis. Results: 43.8% of patients who increased to a weekly dose of 80 mg clinically improved at their follow-up, compared with 33.3% of those who stayed at a weekly dose of 40 mg. The dose increase led to a statistically significant increase in serum concentration of adalimumab ( P < .001). Higher serum adalimumab concentration is associated with lower disease activity ( P = .043). Normal-weight patients had significantly higher concentrations than overweight patients ( P = .011). Conclusions: An increase in the weekly dose of adalimumab led to a nonstatistically significant improvement in clinical response but led to a statistically significant increase in serum concentration.
Short-term WB-EMS in Cancer Patients: Positive Effects After 2 Weeks of Exercise—A Single-arm Trial
Authors: Kersten Jane , Niels Timo , Tomanek Annika , Baumann Freerk T. 
Published: January 2025

Context Due to therapeutic side effects and physical weakness, patients are not always able to carry out strenuous and lengthy exercises. Hence, this study investigated the effectiveness and feasibility of a short-term Whole-body electromyostimulation (WB-EMS) for oncological patients during and after anticancer treatment. The primary aim was to ensure the feasibility of WB-EMS training. Furthermore, the effects of WB-EMS training were investigated over a period of 2 weeks on parameters such as quality of life, body composition and physical performance. Method Thirteen cancer patients with different diagnosis, disease stages and treatment state were included. They participated in supervised WB-EMS sessions 4 times over a 2-week period. Physical functioning, body composition, depression, fatigue, and quality of life were measured before and after the intervention period. Moreover, a pre-post measurement of the patients’ perceived body constitution was conducted in every exercise session. Results All included patients (n = 13) were able to complete the 4 WB-EMS sessions. At the end of the 2 weeks, a significant increase of the muscle strength could be observed. Additionally, patients improved their cardiovascular fitness. The body composition analyses showed significant reductions in body lean mass and extracellular water. Muscle mass remained unchanged. Furthermore, patients reported an improved perceived body constitution reduced pain and discomfort following all 4 WB-EMS sessions. Conclusion This study suggests that WB-EMS is safe and feasible for cancer patients. Furthermore, it showed that even after 2 weeks, improvements concerning the physical performance and patient-reported outcomes can be achieved. This study indicates benefits of WB-EMS as short-term exercise methode in cancer patients, that could be utelised in fields such as cancer prehabilitation. Trial Registration This trial has been registered with the ISRCTN-Registry (ISRCTN68069634).
A concept analysis of the recurrence-related to diabetic foot ulcers
Authors: Ahmed Bootan Hasan , Voss Joachim G. , Griggs Stephanie , Naif Ahmed A. , Aggarwal Sugandha , Ruksakulpiwat Suebsarn , Schiltz Nicholas K. 
Published: January 2025

Background and Purpose There is inconsistency and lack of conceptual clarity regarding the concept of “recurrence” in diabetes-related foot ulcers. Therefore, the purpose of this concept analysis is to analyze the concept of recurrence-related to diabetes-related foot ulcer after the healing of a previous foot ulcer. Method The Rodger's evolutionary concept analysis method was employed to analyze the concept of recurrence in diabetes-related foot ulcers. Eight databases, including PubMed, EMBASE, CINAHL Plus with Full Text, MEDLINE with Full Text (EBSCO), Web of Science, Cochrane Library, PsychoINFO, and Scopus, were searched. Additionally, Google Scholar, bibliographies, and hand searching were conducted. The search spanned from inception through August 13, 2023, yielding 3290 studies. Among these, 3242 did not meet the inclusion criteria, leaving 46 articles that fulfilled the criteria. Findings In a majority of the studies (n = 20, 43%), diabetes-related foot ulcer recurrence occurred at the same site after the healing of previous foot ulcers. In contrast, in fourteen (20%) studies, the diabetes-related foot ulcer recurrence was described as not at the same site as the previous foot ulcer. In the other twelve (26%) studies, the attribute of recurrence was not identified. Conclusions The concept of recurrence-related to diabetes-related foot ulcer should be reserved for diabetes-related foot ulcers at the same site after the healing of previous foot ulcers.
Comparing immunotherapy effectiveness for unresectable hepatocellular carcinoma: infiltrative versus non-infiltrative types in real-world settings
Authors: Chiang Chien-Ming , Huang Kuan-Kai , Lee Chun-Te , Hong Tzu-Chun , Wu Juei-Seng , Wu Hung-Tsung , Chang Ting-Tsung , Liu Yi-Sheng , Chen Wei-Ting , Wang Chung-Teng , Chang Chen , Chen Po-Jun , Hsieh Ming-Tsung , Chen Chiung-Yu , Chuang Chiao-Hsiung , Lee Ching-Chi , Lin Sheng-Hsiang , Lin Yih-Jyh , Kuo Hsin-Yu 
Published: January 2025

Background: Infiltrative hepatocellular carcinoma (HCC) is often associated with an unfavorable prognosis, posing a challenge in determining the optimal therapeutic approach. Immunotherapy, employing immune checkpoint inhibitors (ICIs), has become a preferred first-line treatment for advanced HCC. However, the overall effectiveness of ICIs in patients with infiltrative HCC remains unclear. This study aims to compare the effect of ICI treatment on clinical outcomes between patients with infiltrative and non-infiltrative HCC. Materials and methods: A retrospective cohort consisting of unresectable HCC patients who underwent immunotherapy with ICIs, categorized into infiltrative and non-infiltrative groups was studied. Primary outcomes comprised treatment response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, progression-free survival (PFS), and overall survival (OS). Results: Of 198 patients, 60 (30.3%) had infiltrative HCC, while 138 (69.7%) had non-infiltrative HCC. In the infiltrative group, the objective response rate (ORR) was 36.7% and the disease control rate (DCR) was 55.0%. For the non-infiltrative group, the ORR was 33.3% and the DCR was 56.5%, showing no significant difference between the two groups. However, patients in the infiltrative group had significantly shorter median of PFS and OS following immunotherapy, with a PFS of 4.1 months (95% CI: 2.5–6.7; p = 0.0409) and an OS of 10.4 months (95% CI: 6.7–14.4; p = 0.0268), compared with the non-infiltrative group, which had a PFS of 5.5 months (95% CI: 3.2–7.6) and an OS of 17.0 months (95% CI: 12.8–21.8). Conclusion: For immunotherapy, infiltrative HCC exhibits treatment responses similar to non-infiltrative HCC. Nonetheless, infiltrative HCC is associated with shorter survival outcomes, compared with non-infiltrative type. Our findings emphasize the essential of considering type discrepancies when developing management strategies for immunotherapy.
Different Times for Different Metrics: Predicting 90 Days of Intermittently Scanned Continuous Glucose Monitoring Data in Subjects With Type 1 Diabetes on Multiple Daily Injection Therapy. Findings From a Multicentric Real-World Study
Authors: Csermely Alessandro , Borella Nicolò D. , Turazzini Anna , Pilati Martina , Sheiban Sara S. , Bonadonna Riccardo C. , Trevisan Roberto , Trombetta Maddalena , Lepore Giuseppe 
Published: January 2025

Aims: According to the 2023 International Consensus, glucose metrics derived from two-week-long continuous glucose monitoring (CGM) can be extrapolated up to 90 days before. However, no studies have focused on adults with type 1 diabetes (T1D) on multiple daily injections (MDIs) and with second-generation intermittently scanned CGM (isCGM) sensors in a real-world setting. Methods: This real-world, retrospective study included 539 90-day isCGM data from 367 adults with T1D on MDI therapy. For each sensor metric, the coefficients of determination ( R2) were computed for sampling periods from 2 to 12 weeks versus the whole 90-day interval. Correlations were considered strong for R2 ≥0.88. Results: The two-week sampling period displayed strong correlations for time in range (TIR, 70-180 mg/dl; R2 = 0.89) and above range (TAR, >180 mg/dl; R2 = 0.88). The four-week sampling period showed additional strong correlations for time in tight range (TITR, 70-140 mg/dl; R2 = 0.92), for the coefficient of variation (CV; R2 = 0.88), and for the glycemia risk index (GRI; R2 = 0.92). The six-week sampling period displayed an additional strong correlation for time below range (TBR, <70 mg/dl; R2 = 0.90). After stratification by clinical variables, lower R2 values were found for older age quartiles (>40 years), higher CV (>36%), lower sensor use (≤94%), and higher HbA1c (>7.5%). Conclusion: In patients with T1D on MDI, two- to six-week intervals of isCGM use can provide clinically useful estimates of TIR, TAR, TITR, TBR, CV, and GRI, which can be extrapolated to longer (up to 90 days) time intervals. Longer intervals might be needed in case of older age, higher glucose variability, lower sensor use, and higher HbA1c.
Apparent diffusion coefficient and magnetic resonance imaging characteristics in predicting response to radiosurgery in patients with vestibular schwannomas
Authors: Pitukkitronnagorn Nattapon , Chakkabat Chakkapong , Jittapiromsak Nutchawan 
Published: January 2025

Objective Predicting treatment response in patients with vestibular schwannomas (VSs) remains challenging. This study aimed to evaluate the use of pre-treatment normalized apparent diffusion coefficient (nADC) values and magnetic resonance (MR) imaging characteristics in predicting treatment outcomes in patients with VSs undergoing radiosurgery. Methods The MR images of 44 patients with VSs who underwent radiosurgery at our institution were retrospectively reviewed, and the patients were categorized into tumor control ( n = 28) and progression ( n = 16) groups based on treatment response after treatment initiation, with a median follow-up duration of 29.5 (13–115) months. Pre-treatment nADC values for the whole tumor and solid portion of the tumor were assessed for predictive significance. MRI characteristics were analyzed, including hemorrhage status, tumor morphology, and post-treatment loss of central enhancement. Interobserver reliability was also evaluated. Results Early post-treatment enlargement was associated with tumor progression ( p = .024). The mean pre-treatment nADC values for the solid part of the tumor were significantly higher in the tumor control group than in tumor progression group (1.32 vs 1.05, p = .005). The receiver operating characteristic curve analysis revealed a mean nADC of 1.18 as an optimal cutoff, with sensitivity and specificity of 76.2% and 86.7%, respectively, in predicting treatment response. Conclusion The mean nADC values for the solid part of the tumor demonstrated predictive value for treatment response, with implications for treatment planning. Notably, early post-treatment enlargement was correlated with tumor progression. Incorporating these findings into clinical practice may refine treatment strategies for patients with VSs undergoing radiosurgery.
Distribution and antifungal susceptibility of Candida species causing vulvovaginal candidiasis and urinary tract infection in Medlatec healthcare system, Ha Noi city, Vietnam in 2023
Authors: Ngai Pham Van , Dat Tran Huu , Nhi Luu Yen , Linh Tran Thi Khanh , Thu Nguyen Thi , Anh Vu Lan , Dung Bui Thi Thu , Tran Pham Van , Hien Nguyen Thi , Son Nguyen Thai , Que Trinh Thi , Anh Do Ngoc 
Published: January 2025

Background: Vulvovaginal candidiasis and urinary tract infections caused by Candida are common diseases. While the most common causative agent is C. albicans, other species, such as non- C. albicans, can also be responsible. Susceptibility to antifungal drugs varies among Candida species, but there is very limited information available from Vietnam. Objectives: To determine the species distribution and antifungal susceptibility patterns of Candida isolated from urine and vaginal samples of patients tested at the Medlatec healthcare system in 2023. Design: Cross-sectional study. Methods: The study describes a cross-sectional analysis of over 102 Candida isolates obtained from urine and vaginal samples of patients using the testing services at Vietnam Medlatec healthcare system from January to December 2023. Species identification of Candida isolates was performed using germ tube test and Vitek® 2 systems. Antifungal susceptibility testing was carried out using the VITEK® 2 card for yeast fungi. Minimum inhibitory concentrations for these isolates were classified according to the Clinical and Laboratory Standards Institute guidelines (M27-A3 and M27M44S-ED3). Results: In this investigation, five different Candida species were identified. Among these isolates, C. albicans (78.43%) was the most frequent, followed by C. tropicalis (11.76%), C. glabrata (4.91%), C. parapsilosis (1.96%), and C. krusei (0.98%). The resistance rates to fluconazole, voriconazole, caspofungin, micafungin, and amphotericin B were 7.7%, 4.2%, 4.0%, 1.0% and 1.0%, respectively. Conclusion: The most common species found in this population was C. albicans. Our findings also showed a high frequency of non- albicans Candida species causing fungal urinary tract infections. The resistance rates of isolated Candida strains to echinocandins and amphotericin B were low, while some strains were found to be resistant to fluconazole and voriconazole.